Clinical Trials · NCT06824051
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 120
- Start date
- Feb 2025
- Locations
- 4 sites, United States
- Primary endpoint
- Percent Change from Baseline in Visceral Adipose Tissue (VAT)